Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack mystery: imaging study aims to uncover hidden causes

NCT ID NCT02905357

Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 450 people who had a heart attack but no major blockages in their heart arteries (called MINOCA). Using advanced imaging, researchers aim to find the real cause, such as plaque disruption or artery tears. Participants are followed every 6 months for up to 10 years to track future health events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 450 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2016

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Men and women with MI and no coronary stenosis of 50% or greater on angiography, consecutive.

Ages

21 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms * Objective evidence of MI (either or both of the following): * Elevation of troponin to above the laboratory upper limit of normal * ST segment elevation of ≥1mm on 2 contiguous ECG leads * Willing to provide informed consent and comply with all aspects of the protocol * Age ≥ 21 years Exclusion Criteria: * Stenosis ≥50% of any major epicardial vessel on invasive angiography, as determined by the angiographer at the time of clinically ordered cardiac catheterization * History of known obstructive coronary artery disease at angiography, including history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) * Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month) * Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma * Coronary dissection apparent on angiography * Excessive coronary tortuosity which, in the angiographer's opinion, increases the risks of OCT * eGFR\<45 or contraindication to additional contrast needed for OCT in the opinion of the angiographer or treating physician * Contraindication to MRI (including but not limited to ferromagnetic implants) * Pregnancy * Thrombolytic therapy for STEMI (qualifying event)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Columbia University Medical Center/NYPH

    New York, New York, 10032, United States

  • Dartmouth-Hitchcock

    Lebanon, New Hampshire, 03766, United States

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Golden Jubilee National Hospital

    Clydebank, Scotland, G81 4DY, United Kingdom

  • Johns Hopkins Medical Center

    Baltimore, Maryland, 21287, United States

  • NYU Langone Medical Center

    New York, New York, 10016, United States

  • NYU Winthrop

    Mineola, New York, 11501, United States

  • Ohio State University Medical Center

    Columbus, Ohio, 43210, United States

  • Seton Heart (Ascension) Univeristy of Austin, Texas

    Austin, Texas, 78705, United States

  • St. Boniface General Hospital

    Winnipeg, Manitoba, R2H 2A6, Canada

  • St. Luke's University Health Network

    Bethlehem, Pennsylvania, 18015, United States

  • Stanford University

    Stanford, California, 94305, United States

  • UC San Diego Medical Center

    San Diego, California, 92103, United States

  • University of Alabama-Birmingham

    Birmingham, Alabama, 35294, United States

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of Calgary

    Calgary, Canada

  • University of Florida Medical Center

    Gainesville, Florida, 32603, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213, United States

  • Vancouver General Hospital

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.